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Avances en la inmunosupresión para el trasplante renal.
Nuevas estrategias para preservar la función renal y
reducir el riesgo cardiovascular
RESUMEN
El interés principal en el desarrollo de nuevos inmunosupre-
sores para el trasplante renal no sólo radica en la mejora
de los resultados a corto plazo, sino también en 
un mejor perfil de seguridad, una menor nefrotoxicidad y
un mejor perfil cardiovascular y metabólico. Belatacept es
una proteína de fusión que bloquea la coestimulación de los
linfocitos al unirse a los antígenos CD80 y CD86. En los estu-
dios clínicos, especialmente BENEFIT y BENEFIT-EXT, se ha de-
mostrado que belatacept preserva la función y la estructura
del injerto renal y que sus efectos se mantienen a largo pla-
zo. En comparación con los inhibidores de la calcineurina, be-
latacept se asocia a una menor incidencia de nefropatía cró-
nica del injerto y ofrece un perfil cardiovascular y metabólico
más favorable. Su eficacia y seguridad se mantienen en tras-
plantes renales de donantes con criterios ampliados.
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ABSTRACT
The development of new immunosuppressants for renal
transplantation is aimed not only at improving short-term
outcomes, but also at achieving better safety, cardiovascu-
lar, and metabolic profiles and at decreasing nephrotoxici-
ty. Belatacept is a fusion protein that inhibits T cell activa-
tion by binding to CD80 and CD86 antigens. Clinical trials,
particularly the BENEFIT and BENEFIT-EXT studies, have
shown that belatacept preserves function and structure in
renal grafts. The effects of belatacept provide long-term,
sustained results, and the safety and efficacy of this drug
have been demonstrated in cases of renal transplantation
from expanded criteria donors. Compared to calcineurin
inhibitors, belatacept is associated with a lower incidence
of chronic allograft nephropathy and a more favourable
cardiovascular and metabolic profile.
Keywords: Belatacept. Renal function. Kidney transplantation.
INTRODUCTION
The objective of immunosuppression in kidney
transplantation is to prevent and treat acute rejection and
avoid chronic graft damage, thus minimising the adverse
effects of immunosuppressants. The introduction of
cyclosporine, tacrolimus, and mycophenolate mofetil (MMF)
reduced rates of acute rejection and improved short and mid-
term graft survival,1,2 as reported by data from the Organ
Procurement and Transplantation Network (OPTN) and the
Scientific Registry of Transplant Recipients (SRTR) in the
United States,3 and the Grupo Español para el Estudio de la
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Nefropatía Crónica del Trasplante (Spanish Chronic
Allograft Nephropathy Study Group).4
However, the decrease in acute rejection rates has not been
associated with increased long-term graft survival.5 Results
from the OPTN/SRTR 2009 report showed no significant
differences over time (Table 1).3 As such, strategies are still
being sought that can increase long-term graft survival and
patient survival.
Chronic graft dysfunction continues to be a common cause
of graft loss. In the Spanish ICEBERG epidemiological
study, 55.5% of patients developed chronic allograft
nephropathy during a follow-up period of 8 years, average.6
In a Spanish study involving 1029 kidney recipients between
1997 and 2007, no significant differences in graft survival
were observed after 5 and 10 years when only analysing
cases where the graft had already survived more than 12
months.7 In the second phase of the study by the Spanish
Chronic Allograft Nephropathy Study Group, patients that
received a kidney transplant in 2002 were also included.8
Twelve months after the transplant, mean estimated
glomerular filtration rate (eGFR) was
51.7±18.8ml/min/1.73m2. During the follow-up period that
lasted a mean 74.0±43.9 months, eGFR decreased by a mean
1.6±6.24ml/min/year. This decrease was more pronounced in
patients treated with cyclosporine (n=3163) than those
treated with tacrolimus (n=1044) and the difference was
even greater with respect to those not receiving calcineurin
inhibitors (n=133; drugs not specified).9
Cardiovascular disease following a kidney transplant was
researched by the Spanish group Forum Renal, which
created a prospective, multi-centre database of 2600 kidney
transplantations during the period of 2000-2002. The rate of
acute rejection at 12 months was 14.8%. After 4 years, graft
and patient survival were 85.6% and 91.7%, respectively.
The leading cause of death was cardiovascular disease,
mainly coronary disease during the first year. The primary
causes of graft loss were: vascular disease and thrombosis
during the first year, death with a functioning graft in the
second and third years, and chronic allograft nephropathy in
the fourth year.10
In addition to chronic allograft nephropathy and
cardiovascular morbidity and mortality rates, infectious
morbidity and mortality,11 metabolic complications,12 and a
high frequency of tumours all impede long-term success.13
The primary interest in developing new immunosuppressants
no longer involves simply improving short-term results, but
also improving the safety profile, lowering nephrotoxicity,
and improving cardiovascular and metabolic profiles.14
Furthermore, the tolerability and adverse effects of
immunosuppressants are just as important as their efficacy,
above all when taking into account that kidney transplant
recipients are growing older, with associated cardiovascular
comorbidities.15
NEW IMMUNOSUPPRESSANTS FOR KIDNEY
TRANSPLANTS
The currently used immunosuppressant regimens are
designed to block the activation, proliferation, and
functioning of T cells (TC).16 The activation and proliferation
of TC depends on three signals. The first is given by the
interaction between the TC receptor and class II molecules,
expressed in antigen presenting cells (APC). Calcineurin is
activated at this point, and this is where calcineurin
inhibitors, such as cyclosporine and tacrolimus, come into
play. The second signal, or costimulatory signal, depends on
the interaction of CD80/86 in the APC and CD28 expressed
in the TC surface. Belatacept inhibits this interaction. The
Table 1. Evolution of graft and patient survival between 1998 and 2007, according to the OPTN/SRTR 2009 report
Graft survival (%) Patient survival (%)
Deceased donor Living donor Deceased donor Living donor
1 year 3 years 5 years 10 years 1 year 3 years 5 years 10 years 1 year 3 years 5 years 10 years 1 year 3 years 5 years 10 years
1998 88.8 78.2 66.9 42.8 94.7 88.1 80.4 58.9 94.8 88.6 81.7 61.5 97.8 94.8 90.1 76.8
2003 89.1 78.5 68.6 na 95.4 88.4 81.0 na 94.5 88.2 81.4 na 98.2 94.9 90.8 na
2005 90.0 80.3 na na 95.1 89.2 na na 94.6 88.7 na na 98.0 95.2 na na
2007 91.5 na na na 96.6 na na na 95.9 na na na 98.7 na na na
na: not available.
(Source: reference No. 3).
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25.7% vs 4.5% (P=.001). The difference in acute rejection
rates, 23.6% with sotrastaurin compared to 4.5% with
tacrolimus (P=.003) caused the interruption of the study.30
CP-690550 or tofacitinib (previously referred to as
tasocitinib) is a selective inhibitor of JAK3 kinase which
plays a central role in signal transduction for cytokine
receptors.31 In phase II trials, tofacitinib has demonstrated
comparable efficacy to tacrolimus in terms of acute rejection
and renal function.14,32 In a pilot trial, the lower dose of CP-
690550 had similar safety and efficacy profile to tacrolimus
in kidney transplant recipients.33 Later, a multi-centre,
randomised study was carried out in which 322 kidney
transplant recipients were randomised to receive CP-690550
or cyclosporine for 12 months. The incidence of acute
rejection was similar in both groups, although severe
infections were more common with CP-690550 than with
cyclosporin.34 However, eGFR improved with CP-690550
from the 1st month, and the effect was maintained throughout
the study, with significantly different results from
cyclosporine (P<.05 for both regimens of CP-690550).35
Alefacept is a humanised anti-CD2 monoclonal antibody. It
is a LFA3-IgG1 fusion protein that inhibits the adhesion of T
cells. The results of alefacept in kidney transplants in
primates were very promising,36 which led to further phase I
and II trials, administering the drug orally along with
tacrolimus in kidney transplants. However, the results from a
randomised, double-blind, placebo controlled, multi-centre,
phase II trial with 212 kidney transplant recipients did not
confirm these expectations. Alefacept did not result in
significantly superior outcomes than the placebo, except for
in the activation of CD4+ and CD8+ T cells, with no
differences in graft survival, patient survival, or renal
function.37
BELATACEPT
Belatacept is a selective T-cell blocker. It is a human fusion
protein that combines a modified extracellular portion of
cytotoxic T-cell antigen 4 (CTLA-4) and the fragment
crystallisable region of human IgG1 (Fc region). It blocks
the costimulatory signal by binding to APC CD80 and CD86
antigens, thus inhibiting the complete activation of T cells
and promoting anergy and apoptosis. This drug is derived
from abatacept, a fusion protein that is effective in
autoimmune disorders such as rheumatoid arthritis. The
belatacept molecule includes two replaced amino acids that
confer a greater binding ability to CD80 and CD86, greater
binding strength to T cells, and greater efficacy in
prophylaxis against rejection.38
In June 2011, the European Medicines Agency (EMA)
approved belatacept for combined use with steroids and
mycophenolic acid in prophylaxis against graft rejection in
first and second signals activate transduction pathways that
generate transcription factors for the synthesis of cytokines.
Among these, interleukin 2 (IL-2) stands out, as it induces
the third signal, allowing for the proliferation of TC clones
(this is where immunosuppressants that interfere with the
cell cycle play a role). Several strategies have been
developed for improving kidney transplant results using
traditional immunosuppressants,13,17-26 but the rates of chronic
transplant nephropathy and cardiovascular and metabolic
risk oblige us to continue seeking out alternatives.
Several different drugs and biological agents are being
evaluated in clinical trials or have recently been approved for
immunosuppression in kidney transplants. These new
immunosuppressants have different mechanisms of action.
Some inhibit enzymes such as protein kinase C (PKC) or
Janus kinase 3 (JAK3), and others act on key components of
the lymphocyte activation process, such as the LFA3-CD2 or
CD28-CD80/86 pathways (Figure 1).27
Sotrastaurin is a potent and selective inhibitor of classic (α
and β) and new (δ, ε, η and 0−) isoforms of PKC. These
isoforms play a key role in the first and second signals for
TC activation. By inhibiting these isoforms, sotrastaurin
blocks the initial activation of T cells, although it does not
affect the lymphocyte proliferation that is mediated by IL-
2.28 Two phase II trials were interrupted due to an increase in
acute rejection.14,29 In another phase II trial, sotrastaurin was
compared to tacrolimus in 125 patients that received a
kidney transplant (de novo recipients). After 3 months,
sotrastaurin was significantly less effective than tacrolimus
using the primary evaluation criteria (acute rejection
confirmed by biopsy, graft loss, death, or loss to follow-up),
Figure 1. Intracellular signalling and inhibition by new
compounds.
(Source: reference No. 28).
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adult patients that had received a kidney transplant.39 This is
the first biological agent to be approved for this indication,
and is the first immunosuppressant in a decade to offer a
new mechanism of action.
Belatacept has linear pharmacokinetics in healthy volunteers
and kidney transplant recipients. Patient exposure to the drug
is proportional to dosage, with very little day to day
variability. Drug levels in the body are predictable based on
the doses administered intravenously, regardless of sex, age,
race, renal function, albuminemia, diabetes, and dialysis
treatment.40 In clinical trials, the minimum concentration was
maintained stably up to 5 years following the transplant.41
The saturation of CD 86 receptors inhibit the T-cell
alloresponse. In vitro studies have demonstrated
alloresponse inhibition with the minimum concentration of
belatacept necessary to saturate CD86 receptors. In patients
treated with belatacept, free CD86 receptor levels are
significantly lower than before treatment, and are also lower
than in healthy volunteers and patients treated with
cyclosporin.42 The extension to 5 years of a phase II trial
involving patients treated with belatacept or cyclosporine,
CD86 receptor saturation with belatacept was maintained
throughout the follow-up period. However, belatacept
saturation in patients treated every 4 weeks (74%) was
significantly higher than in patients treated with belatacept
every 8 weeks (56%) (P<.05),41 confirming that saturation of
CD86 receptors depends on the frequency and dosage of
belatacept administered.
Phase II trials
A randomised, partially blinded study with parallel groups
carried out in 22 centres in Europe, USA, and Canada, and
involving 216 patients, compared belatacept administered in
more intensive (MI) or less intensive (LI) treatment
schedules vs cyclosporine in the prevention of rejection
within 6 months of transplantation.38 The incidence of acute
rejection within 6 months was similar between the three
groups: 7% with MI belatacept, 6% with LI belatacept, and
8% with cyclosporine. There were no cases of rejection after
6 months. Directly measured GFR was higher with
belatacept after 12 months (Figure 2). The best correlations
between GFR and eGFR were achieved using the
Modification of Diet in Renal Disease (MDRD) equation.
Chronic allograft nephropathy was less frequent with
belatacept (Figure 3). Patients with chronic allograft
nephropathy that received belatacept had a higher eGFR
than the group that received cyclosporine. In terms of
cardiovascular and metabolic profiles, blood pressure, and
lipid levels in patients treated with belatacept were similar or
slightly lower than in the group treated with cyclosporine,
despite the greater use of anti-hypertensive and lipid-
lowering drugs in this group.
This study demonstrated that belatacept was not inferior to
cyclosporine, and even suggested that belatacept could
preserve GFR and reduce the incidence of chronic allograft
nephropathy.38
In order to evaluate the long-term efficacy and safety of
belatacept, 102 patients treated with belatacept (90%) and 26
treated with cyclosporine (51%) from the previous study
completed 60 months of treatment.41 The percentages of
participation show good acceptance of belatacept. Renal
function remained stable throughout the study in patients
treated with belatacept, with an eGFR (MDRD) of
75.8±20.1ml/min/1.73m2 12 months after the transplant, and
77.2±22.7ml/min/1.73m2 after 5 years. In contrast, eGFR
decreased in the group treated with cyclosporine
Figure 2. - Both treatment schedules of belatacept were
significantly superior to cyclosporine in terms of renal
function.
a P=.01 as compared to cyclosporine; b P=.04 as compared to
cyclosporine. For the comparison of both treatment schedules
of belatacept vs cyclosporine, P<.05.
LI: least intensive treatment; MI: most intensive treatment.
(Source: reference No. 38).
Figure 3. Chronic allograft nephropathy was less frequent
with both treatment schedules of belatacept.
LI: least intensive treatment; MI: most intensive treatment.
(Source: reference No. 38).
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(74.4±23.7ml/min/1.73m2 after 12 months and
59.3±15.3ml/min/1.73m2 after 5 years).
As regards cardiovascular risk factors, there was a slight
increase in systolic and diastolic blood pressure between
months 24 and 60 in patients treated with cyclosporine, with
final values of 138±18.9mm Hg and 83±8.9mm Hg,
respectively, compared to 125±13.9mm Hg and 76±10.1mm
Hg with belatacept (note: no P-values are available, data
extracted from Table 1 in Vincenti, 2010). The levels of non-
HDL cholesterol decreased in both groups, although the use
of lipid-lowering drugs was lower in patients treated with
belatacept. When the study period was extended to a long-
term period, the frequency of new-onset diabetes after
transplantation (NODAT) was similar in the two groups.
The incidence rates of death/graft loss and acute rejection
were low. The incidence of severe infections was 16% with
belatacept and 27% with cyclosporine. Neoplasia occurred in
12% of patients in both groups, with only one case of post-
transplant lymphoproliferative disorder (PTLD) in the
cyclosporine group and none in the belatacept group.
Coronary disease was more common in the cyclosporine
group (12% vs 2% with belatacept).
The study demonstrated good compliance with treatment,
stable renal function, a high level of safety, and predictable
pharmacokinetics with belatacept during a 5-year follow-up
period. No new cases of PTLD occurred with belatacept.41
In an open, randomised, controlled phase II trial, kidney
transplant recipients were treated with belatacept/MMF
(n=33), belatacept/sirolimus (n=26), or tacrolimus/MMF
(n=30) for 12 months. The incidence of acute rejection after
6 months was 12% with belatacept/MMF, 4% with
belatacept/sirolimus, and 3% with tacrolimus/MMF. Renal
function was better with the two different belatacept
regimens, with a mean eGFR (MDRD) that was 8-
10ml/min/1.73m2 higher than in the tacrolimus/MMF group.
There were no significant differences in terms of safety,
including cardiovascular risk profile.43
This same study demonstrated a potent inhibitory activity in
the combination of belatacept/sirolimus, which can be as
effective as a calcineurin inhibitor (CNI) in halting the
antigen-specific and T-cell response. In the first year of the
study, the percentage of regulatory T cells (Treg) in the
memory T-cell compartment was significantly higher in
patients treated with belatacept/sirolimus. The combination
of depleted T cells, costimulatory blockade, and mTOR
inhibition appears to be effective in preserving Treg and
inhibiting immune responses.44
Another open and randomised phase II trial compared the
replacement of a CNI (cyclosporine or tacrolimus) with
belatacept against continuing treatment with the CNI in 175
patients that had received a kidney transplant 6-36 months
ago and had stable graft function. After 12 months, 6 patients
that had converted to belatacept had developed acute
rejection, but no graft losses occurred. Graft survival was
100% in the group treated with belatacept and 99% in the
group treated with a CNI. Belatacept produced a mean
increase in eGFR (MDRD) of 7.0±11.99ml/min/1.73m2,
whereas the mean increase with a CNI was
2.1±10.34ml/min/1.73m2 (P=.0058). The switch from a CNI
to belatacept improved renal function and was associated
with a low rate of acute rejection.45
In order to evaluate whether the benefits of belatacept were
maintained over long periods, the follow-up protocol was
expanded to 2 years in 162 patients from the previous study.
Mean eGFR was higher with belatacept (62.0ml/min/1.73m2)
than with CNI (55.4ml/min/1.73m2). The mean change in
eGFR from the start of the study was much higher with
belatacept (8.8ml/min/1.73m2) than with calcineurin
inhibitors (0.3ml/min/1.73m2). The benefit of belatacept on
renal function was observed in patients previously treated
with cyclosporine (7.8ml/min/1.73m2) or tacrolimus
(8.9ml/min/1.73m2), and it was independent of renal function
at the start of the study. There were also differences in the
incidence of acute rejection; rejection occurred in 4.9% of
the cases treated with belatacept, and only during the first
year, whereas the rate was 3.7% with CNI, all cases
occurring in the second year. The safety profile was similar
for all groups, and no cases of PTLD were observed.46
Phase III trials
In the international BENEFIT study (Belatacept Evaluation
of Nephroprotection and Efficacy as First-line
Immunosuppression Trial), MI and LI regimens of belatacept
were compared to cyclosporine (Table 1) as maintenance
immunosuppression therapy in 666 kidney recipients. The
primary evaluation criteria were patient and transplant
survival, along with a composite endpoint involving renal
deterioration and incidence of acute rejection. After 12
months, patient/graft survival was similar in the three
treatment groups (95%, 97%, and 93%, respectively).
However, renal function was significantly better with both
belatacept regimens. The composite endpoint of renal
deterioration was reached in 55% of MI belatacept patients
and 54% of LI belatacept patients, as compared to 78% of
patients with cyclosporine (P≤.001 for MI or LI vs
cyclosporine). Mean eGFR was 65ml/min/1.73m2 and
63ml/min/1.73m2 for MI and LI belatacept, respectively,
whereas it was 50ml/min/1.73m2 for cyclosporine (P≤.001
for MI or LI vs cyclosporine). eGFR was calculated using
the MDRD equation. Acute rejections were more common
with belatacept (22% MI and 17% LI) than with
cyclosporine (7%). Safety was similar with both drugs,
although more cases of PTLD occurred with belatacept.47
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In the phase III BENEFIT-EXT study (Belatacept Evaluation
of Nephroprotection and Efficacy as First-line
Immunosuppression Trial-EXTended criteria donors), 543
kidney transplant recipients were evaluated that had received
kidneys from expanded criteria donors. The primary
evaluation criteria were the same as in the BENEFIT study.
There were no significant differences in patient/graft
survival: 71% with MI, 77% with LI, and 85% with
cyclosporine (P=.002 for MI vs cyclosporine and P=.06 for
LI vs cyclosporine). Renal function was significantly better
with belatacept, with an eGFR that was 4-7ml/min/1.73m2
higher (P=.008 for MI vs cyclosporine and P=.1309 for LI
vs cyclosporine). Cardiovascular and metabolic profiles were
better with belatacept. The incidence of acute rejection was
similar between groups (18% for MI and LI and 14% for
cyclosporine).48
The combined data analysis from the BENEFIT and
BENEFIT-EXT studies after 2 years of treatment included
840 patients. The proportion of surviving patients with a
functioning graft was similar between all treatment groups.
Belatacept continued to provide superior results to
cyclosporine in terms of renal function, with an eGFR that
was a mean 16-17ml/min/1.73m2 higher in the BENEFIT
study and 8-10ml/min/1.73m2 higher in the BENEFIT-EXT
study as compared to cyclosporine. Very few episodes of
acute rejection occurred in the second year of the trials.
Cardiovascular and metabolic profiles were better with
belatacept than with cyclosporine. The incidence of PTLD is
greater in patients with negative serology tests for Epstein-
Barr virus (EBV-), and so the efficacy of this drug was
specifically analysed in EBV+ patients, with coinciding
results with those from the overall study population. No new
adverse effects were observed. The authors concluded that
the LI regimen of belatacept was preferable to the MI
regimen, since it provided a better balance between efficacy
and safety.49
The 3-year results from both trials showed that belatacept
maintains its effects on a long-term basis, with high patient
and graft survival rates,50 even in recipients of kidneys from
expanded criteria donors.51
In the BENEFIT study, renal function was better with
belatacept than with cyclosporine from the third month until
the end of the three-year study. Treatment with belatacept
was associated with a greater probability of improved renal
function.52 In the combined analysis of renal function results
from the BENEFIT and BENEFIT-EXT studies, belatacept
was superior (Figure 4 and Figure 5). Change in mean eGFR
(ml/min/year) between months 3 and 36 was 1.0 (MI
belatacept), 1.2 (LI belatacept), and -2.0 (cyclosporine) in
the BENEFIT study, and -0.9, -0.6, and -1.9, respectively, for
the BENEFIT-EXT study. Advanced chronic renal failure
(eGFR<30ml/min) was more common in patients treated
with cyclosporine in both studies: 20% in the BENEFIT
study and 44% in the BENEFIT-EXT study as compared to
MI or LI belatacept: 9% and 10% in the BENEFIT study and
27% and 30% in the BENEFIT-EXT study.53 In another
analysis, renal function results were compared by donor type
(deceased or living donor), with no significant differences
observed in GFR improvement amongst patients treated with
belatacept.54
Safety of belatacept
Clinical studies have demonstrated good tolerance with
belatacept. The safety profile of belatacept was evaluated in
an analysis of the pooled data from the three key belatacept
studies in kidney recipients.38,47,48 The data for 1425 patients
were analysed, with a mean follow-up time of 2.4 years.
With LI belatacept, the death rate (5%) was lower than with
cyclosporine or MI belatacept (7% each), which also
occurred with the rate of neoplasia (32% vs 36% and 37%,
Table 2. Treatments in the BENEFIT study
Treatment Schedule
MI belatacept 0-3 months: 10mg/kg on days 1 and 5 and weeks 2, 4, 6, 8, 10, 12
4-6 months: 10mg/kg on weeks 16, 20, 24
7-12 months: 5mg/kg every 4 weeks
LI belatacept 0-1 month: 10mg/kg days 1 and 5 and weeks 2, 4
2-3 months: 10mg/kg weeks 8, 12
3-12 months: 5mg/kg every 4 weeks
Cyclosporine Initial dose: 4-10mg/kg
0-1 month: adjust dosage to achieve a concentration of 150-300ng/ml
2-12 months: adjust dosage to achieve a concentration of 100-250ng/ml 
LI: least intensive treatment; MI: most intensive treatment.
(Source: reference No. 47).
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respectively). The rate of infection was similar between
patients treated with belatacept and with cyclosporine. One
case of progressive multifocal leukoencephalopathy was
observed in a patient treated with belatacept at higher doses
than recommended, and who was also receiving IL-2
receptor antagonists, MMF, and steroids. The tolerance to
the infusion was good, which facilitated compliance with the
treatment protocol, and no cases of anaphylaxis or
hypersensitivity were reported. According to the results from
this analysis, the LI regimen is preferable to the MI,55 since it
provides a better safety profile that MI and the same
efficacy.
The safety profile analysis for belatacept after 3 years of
treatment in the BENEFIT and BENEFIT-EXT studies
included the data from 1209 patients. LI belatacept was
associated with fewer deaths and cases of severe infection
than MI belatacept and cyclosporine (Table 3).56 The risk of
PTLD with belatacept (1% for each treatment schedule) was
within the expected incidence rate following a kidney
transplant,57 and decreased after 18 months.
Cases of PTLD have arisen in phase II and III trials. There
were 16 cases of PTLD: 8 under the MI regimen (2%), 6
under the LI regimen (1%), and 2 with cyclosporine (0.4%),
9 cases having central nervous system (CNS) problems
among those treated with belatacept (6 with MI and 3 with
LI).55 The risk for developing this condition was greater in
the first 18 months of treatment, in patients on the MI
belatacept regimen and in those with EBV- serology at the
time of transplant. In a later analysis of biopsies by a central
pathologist, two of the cases described as graft PTLD, both
in LI patients, were later diagnosed as acute rejection in one
case and non-specific T-cell proliferation in the other.55
Calcineurin inhibitors increase the risk of infection by
cytomegalovirus (CMV) by inhibiting specific memory T
cells. Results from in vitro studies and seropositive
volunteers for CMV suggest that belatacept protects against
transplant rejection, but does not alter the response of CMV-
specific memory T cells. As a result, belatacept does not
increase the risk of infection by CMV,58 which is known to
be a risk factor for developing PTLD when coexisting with
an EBV infection.
The cardiovascular risk profile for belatacept could be more
favourable than currently used immunosuppressants. In the
BENEFIT and BENEFIT-EXT trials, belatacept was superior
to cyclosporine in the parameters evaluated.59 Mean systolic
blood pressure was 6-9mm Hg lower, and mean diastolic
blood pressure was 3-4mm Hg lower in patients treated with
belatacept than in those treated with cyclosporine (P≤.002).
Non-HDL cholesterol levels were lower with belatacept
(P<.01 with MI or LI belatacept compared to cyclosporine in
both studies), and a similar trend occurred in serum
triglycerides (P<.02 with MI or LI belatacept compared to
cyclosporine in both studies).
In prespecified pooled analysis, NODAT was significantly
less frequent with MI or LI belatacept (5%) than with
cyclosporine (10%) (P<.05 for MI or LI belatacept
compared to cyclosporine). The results from the BENEFIT
and BENEFIT-EXT trials showed that belatacept provides a
better cardiovascular and metabolic profile than
cyclosporin.59
In one of the phase II trials, blood samples were taken at
least every 12 months before the belatacept infusion. The
samples were analysed in a sensitive
electrochemiluminescence immunoassay that was validated
for the detection of anti-belatacept antibodies directed
against the whole molecule or the modified CTLA-4 portion
of belatacept. This type of antibody was detected in six
patients treated with the 4-week treatment regimen and in ten
Figure 4. Glomerular filtration rates when using
belatacept and cyclosporine during the BENEFIT study.
LI: least intensive treatment; MI: most intensive treatment.
(Source: reference No. 53).
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patients treated with the 8-week regimen, although only two
of the patients in the first group and six in the second still
had positive test results on the last follow-up check. Two of
the patients from the 8-week group developed neutralising
antibodies, but both continued treatment. None of the
patients with anti-belatacept antibodies had graft loss or
acute graft rejection, and none died or suffered severe
adverse autoimmune side effects or conditions related to the
infusion.41
In contrast to other immunosuppressants used as the
background treatment in organ transplantation, belatacept
does not require monitoring of drug levels in the body, since
it does not have a narrow therapeutic range.
The risk of interaction with other drugs is very low, since,
in contrast with other immunosuppressants used in
transplants, belatacept is a fusion protein that is not
metabolised by cytochrome P450 enzymes (CYP) or
UDP-glucuronosyltransferase.40
COMMENTS
Belatacept is the first drug in a new class of
immunosuppressants. The data from clinical trials comparing
belatacept to cyclosporine suggest that they have similar
efficacy, but belatacept preserves renal graft structure and
function, and is associated with lower rates of chronic
allograft nephropathy. In long-term treatment regimens,
renal function remained stable, which contrasts with the
annual decrease of 1-3ml/min/m2 that is usually observed
with calcineurin inhibitors at stable doses, and is consistent
with 1st year results.41,60 The recommended initial dose is
10mg/kg on days 1 (before the intervention), 5, 14, and 28,
and after weeks 8 and 12 following the transplantation. In
the maintenance phase, the recommended dose is 5mg/kg
every 4 weeks (±3 days), starting at the end of the 16th week
following the transplant.39
Belatacept offers a more favourable cardiovascular and
metabolic profile than calcineurin inhibitors. According to
the results from a systematic review of randomised and
controlled studies, patients treated with belatacept had a 69%
lower probability of death, compared to those treated with
tacrolimus.61 Cardiovascular disease is the most common
cause of death in patients with kidney transplants and
functioning grafts. In clinical trials such as BENEFIT and
BENEFIT-EXT, the incidence of NODAT with belatacept
has been lower than in patients treated with calcineurin
inhibitors, and belatacept has demonstrated a better
cardiovascular and metabolic profile than currently used
immunosuppressants. In summary, belatacept can provide a
better cardiovascular and metabolic profile than current
immunosuppressants.
Kidney transplants from expanded criteria donors are
becoming more and more frequent due to the increased
demand for organs. However, the risk of graft loss or
dysfunction is higher in these donors, who tend to be
older and have associated morbidity. Graft survival after
one year is lower than in normal organ donors, and
survival in later years is even lower, mainly due to
chronic allograft nephropathy.62,63 The BENEFIT-EXT
study demonstrated that belatacept is effective in
recipients of kidneys from expanded criteria donors, and
its use in this context could prevent nephrotoxicity
associated with calcineurin inhibitors.41
In clinical trials, the primary risk of treatment with
belatacept has been PTLD, especially in the first 18
months of treatment. A relationship has been suggested
between the intensity of immunosuppression and PTLD,
since patients treated with MI belatacept suffered from
CNS-related events more frequently and had a higher
risk of CNS infections. It was proposed that the risk of
PTLD could be reduced by administering the LI
regimen of belatacept and avoiding treatment in EBV-
patients or those with unknown serology,49 since the
primary risk factor is an EBV- serology but CMV
infection and T-cell depletion therapy also increases the
risk. Currently, the technical data sheet for belatacept
states that it is contraindicated in patients with EBV- or
unknown serology.64
Table 3. Safety profile in the BENEFIT and BENEFIT-EXT studies
LI belatacept MI belatacept Cyclosporine
(n=401) (n=403) (n=405)
Deaths 25 (6%) 31 (8%) 32 (8)
Severe adverse effects 270 (67%) 282 (70%) 296 (73%)
Severe infections 144 (36%) 151 (38%) 157 (39%)
Neoplasia (overall) 19 (5%) 16 (4%) 16 (4%)
Post-transplant lymphoproliferative disorder 6 (1%) 5 (1%) 1 (< 1%)
LI: least intensive treatment; MI: most intensive treatment.
(Source: reference No. 56).
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Since CNS involvement in PTLD is more common with
belatacept than cyclosporine, we must keep this possibility
in mind when treating kidney recipients with belatacept who
develop neurological, cognitive, or behavioural symptoms.64
The use of belatacept as the background therapy in kidney
recipients preserves renal function and is associated with a
lower incidence of cardiovascular risk factors and NODAT.
The inclusion of belatacept in immunosuppression protocols
for kidney transplants could facilitate a major improvement
in patient and graft survival.
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